Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Interventional × Cholangiocarcinoma × RRx-001 × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Lymphoma 3 Stomatitis 2 Small Cell Lung Carcinoma 2 Neoplasms 2 Mucositis 2 Mouth Neoplasms 2 Lung Neoplasms 2 Head and Neck Neoplasms 2 Carcinoma, Small Cell 2 Brain Neoplasms 2 Spinal Cord Neoplasms 1 Neuroendocrine Tumors 1 Neoplasm Metastasis 1 Colorectal Neoplasms 1 Cholangiocarcinoma 1 Central Nervous System Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Ovarian Epithelial 1 Carcinoma, Non-Small-Cell Lung 1

Interventions

Gemcitabine 96 Cisplatin 63 Oxaliplatin 38 pembrolizumab 30 Fluorouracil 29 Capecitabine 29 durvalumab 26 Leucovorin 23 lenvatinib 21 Radiofrequency Ablation 11 Nivolumab 11 Magnetic Resonance Spectroscopy 11 Irinotecan 11 apatinib 10 Drug Therapy 10 Albumin-Bound Paclitaxel 10 pemigatinib 9 Taxes 9 Radiotherapy 9 tislelizumab 8 Specimen Handling 8 Floxuridine 8 Bevacizumab 8 tremelimumab 7 Folfox protocol 7 Carboplatin 7 Biopsy 7 130-nm albumin-bound paclitaxel 7 sintilimab 6 atezolizumab 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02452970 2024-04-24

EPIC

EpicentRx, Inc.

Phase 2 Terminated

4 enrolled 6 charts

Gastrointestinal

Cholangiocarcinoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡